Home > Riviste > Italian Journal of Dermatology and Venereology > Fascicoli precedenti > Articles online first > Giornale Italiano di Dermatologia e Venereologia 2020 Dec 14

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

 

Giornale Italiano di Dermatologia e Venereologia 2020 Dec 14

DOI: 10.23736/S0392-0488.20.06878-9

Copyright © 2020 EDIZIONI MINERVA MEDICA

lingua: Inglese

Analysis of key markers: IL-10/sHLA-G in psoriasis patients and the identification of 14-bp INDEL in the HLA-G gene

Martyna BIENIEK-KOBUSZEWSKA 1 , Agnieszka OWCZARCZYK-SACZONEK 1, Agata MACIEJEWSKA-RADOMSKA 2, Paweł WOJTACHA 3, Waldemar PLACEK 1

1 Department and Clinic of Dermatology, Sexually Transmitted Diseases and Clinical Immunology, Faculty of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland; 2 DermArt Polyclinic, Gdynia, Poland; 3 Department of Industrial and Food Microbiology, Faculty of Food Sciences, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland


PDF


BACKGROUND: Psoriasis is a chronic inflammation resulting from interactions between immunological and genetic factors. An important tolerogenic role in this autoimmunological disease is played by HLA-G, which is modulated by IL-10. Therefore, this study (N=80) aimed to evaluate changes in the serum sHLA-G and IL-10 levels in active psoriasis vulgaris and in the early stages of treatment with Methotrexate (MTX) compared to healthy controls. The 14-bp INDEL of the HLA-G gene was evaluated to find possible associations with clinical and laboratory variables.
METHODS: The level of sHLA-G and IL-10 in serum was evaluated (ELISA tests) in patients before the first dose of MTX and at week 12 of treatment, compared to healthy control donors. The 14-bp INDEL in 3’UTR of the HLA-G gene was identified using gDNA templates isolated from full blood. HLA-G amplicons were obtained by PCR, separated by electrophoresis and sequenced.
RESULTS: The mean serum IL-10 level was 4.653 ±3.33 pg/mL in psoriatic patients, 13.3 ± 9.64 pg/mL after short MTX treatment, compared to 6.23 pg/mL in healthy controls. In addition, the serum level of sHLA-G was 0.275± 0.03 ng/mL and 0.332 ± 0.06 ng/mL in patients before and after MTX treatment, respectively, and 0.302±0.08 ng/mL in the control group. A correlation was found (r= -0.43; p<0.005) between the IL-10 and BSA serum levels in psoriasis patients after MTX treatment, indicating health improvement. The three genotypes identified in the 3’UTR of the HLA-G revealed no association with sHLA-G level in serum.
CONCLUSIONS: The mean levels of sHLA-G and the key anti-inflammatory cytokine IL-10 in the blood of pre-treatment psoriasis patients are low and indicate that the immunotolerance mechanisms have failed. Treatment of psoriasis patients with low systemic levels of sHLA-G and IL-10 brings them to the same or higher protein levels, respectively, as in healthy donors. Higher sHLA-G levels in healthy donors and after MTX treatment, compared to the sHLA-G levels in the acute phase of psoriasis, indicates its immune system surveillance function.


KEY WORDS: IL-10; sHLA-G; Psoriasis

inizio pagina